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abundance and accessibility of specific targetable molecules 
and selection of patients who may benefit from the addition 
of targeted agents to radiotherapy. In the nearby future, the 
combination of tracers with a long and a short half-life may 
facilitate simultaneous imaging of different tumour 
characteristics. Furthermore, the introduction of integrated 
PET-MRI imaging will most likely provide a combination of 
superior anatomical and functional information. 
Small studies employing adaptive radiotherapy based on 
functional dynamics and early response mechanisms 
demonstrate promising results. However, each PET tracer has 
demonstrated its potential as well as pitfalls regarding 
application in everyday clinical practice. Further validation in 
multicenter set-up is needed. Immunohistochemistry and 
gene arrays may help to select which therapeutic pathway is 
most suitable for an individual tumour and, therefore, which 
type of molecular PET imaging will be relevant. Ultimately, 
this should result in availability for routine clinical practice 
requiring stable production and accessibility of tracers, 
reproducibility and standardization of imaging and analysis 
methods, as well as general availability of knowledge and 
expertise. 
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Clinical trials are an excellent tool for evaluating the 
effectiveness of a single change in patient management on 
later outcomes.  In the rapidly evolving landscape of clinical 
practice, a plethora of incremental changes may either exert 
a background effect, or be introduced during the conduct of 
a clinical trial.  These can have the effect of blunting, or 
even overwhelming, the impact of the intervention being 
assessed in a randomized study.  Using various examples from 
recently reported clinical trials investigating radiation dose 
escalation, we explore this phenomenon, and speculate on 
how future research may be able to adapt accordingly.  
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Purpose/Objective: Multimodal imaging has the potential to 
increase the accuracy of head and neck squamous cell 
carcinoma target volume delineation. This study aims to 
quantify the variation in Oropharyngeal Squamous Cell 
Carcinoma (OSCC) Gross Tumour Volume (GTV) delineation 
between CT, MR and 18FDG-PET imaging. 
Materials and Methods: A prospective, single centre, pilot 
study was undertaken where 11 patients with locally 
advanced OSCC (2 tonsil, 9 base of tongue primaries) 
underwent pre-treatment, contrast enhanced, 18FDG-PET-CT, 
and T1- and T2-weighted MR imaging, all performed in a 
radiotherapy treatment mask. GTVs were contoured by 6 
clinicians (2 radiologists and 4 radiation oncologists) using CT 
and MRI (T1 and T2 sequences) independently and co-
registered CT and MRI (rigidly co-registered using Mirada RTx 
v1.4, Mirada Medical, Oxford, UK). Clinical information and 
available diagnostic imaging was on hand during contouring. 
A 2 week gap was imposed between individual patient 
delineations to minimise recollection. The semi-automatic 
Schaefer adaptive algorithm contoured the 18FDG-PET GTVs. 
Volume and positional metrics assessed the GTV variation 
with imaging modality. Linear mixed effects models were 
used to determine GTV volume variations, accounting for 
inter-patient and inter-operator variability. Six delineation 
error metrics (described in table 1, ImSimQA, v3.1.5, OSL, 
Shrewsbury, UK) were used to determine the inter-observer 
variability in GTV position within modalities and the variation 
in GTV position between modalities. 
Results: Volumes: The mean GTV volumes were: CT 11.9cm3 
(SD = 4.5cm3); CT-MR 14.1cm3 (SD = 3.7cm3); MR 12.7 cm3 (SD 
= 2.5cm3); and 18FDG-PET 9.5cm3 (SD = 6.8cm3). Significant 
GTV volume differences were found between CT and CT-MR ( 
p < 0.0005), CT-MR and 18FDG-PET ( p < 0.0009) and MR and 
18FDG-PET ( p < 0.016) modalities. MR had a significantly 
smaller inter-operator variability ( p < 0.05) compared to CT. 
Figure 1 shows the GTV volumes for all patients for all 
modalities. 
Positional metrics: The CT inter-observer variability was 
found to be significantly higher ( p <0.05) than both MR and 
CT-MR modalities for all positional metrics except for the 
mean distance to conformity (Table 1). Differences in GTV 
position were found between all modalities with the 




Conclusions: Inter-observer variation using MRI for GTV 
delineation was significantly less than when using CT. The 
use of different imaging modalities (CT, MR and 18FDG-PET) 
produced significantly different GTVs which varied in volume 
